West Nile Virus Drug Discovery
Open Access
- 3 December 2013
- Vol. 5 (12), 2977-3006
- https://doi.org/10.3390/v5122977
Abstract
The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.Keywords
This publication has 168 references indexed in Scilit:
- Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine proteaseAntiviral Research, 2012
- Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitorsAntiviral Research, 2012
- Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse modelAntiviral Research, 2011
- An investigation of phenylthiazole antiflaviviral agentsBioorganic & Medicinal Chemistry, 2011
- Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsHepatology, 2010
- Structure–activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinaseBioorganic & Medicinal Chemistry Letters, 2009
- Closing the door on flaviviruses: Entry as a target for antiviral drug designAntiviral Research, 2008
- Structural proteomics of dengue virusCurrent Opinion in Microbiology, 2008
- Flavivirus methyltransferase: A novel antiviral targetAntiviral Research, 2008
- An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: Synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1-β-d-ribofuranosideBioorganic & Medicinal Chemistry Letters, 2007